AMPH · Amphastar Pharmaceuticals, Inc.
Market Cap
$936.26M
Shares
42.54M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-08-06 | — | |
| 8-K | 2026-07-13 | 2026-07-09 | |
| 8-K | 2026-07-08 | 2026-07-02 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-06-03 | 2026-06-01 | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| 8-K | 2026-05-07 | — | |
| DEF 14A | 2026-04-13 | 2026-06-01 | |
| 8-K | 2026-03-16 | 2026-03-12 | |
| 8-K | 2026-03-06 | 2026-03-03 | |
| 8-K | 2026-03-06 | 2026-03-03 | |
| 8-K | 2026-02-26 | — | |
| 10-K | 2026-02-26 | 2025-12-31 | |
| 8-K | 2026-01-12 | 2026-01-06 | |
| 8-K | 2025-11-06 | — | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-10-24 | 2025-10-21 | |
| 8-K | 2025-09-18 | 2025-09-15 | |
| 8-K | 2025-08-12 | 2025-08-08 | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-07-21 | 2025-07-18 | |
| 8-K | 2025-06-04 | 2025-06-02 | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-05-07 | — | |
| DEF 14A | 2025-04-14 | 2025-06-02 | |
| 10-K | 2025-03-03 | 2024-12-31 | |
| 8-K | 2025-02-27 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-11-06 | — | |
| 8-K | 2024-08-30 | 2024-08-28 | |
| 10-Q | 2024-08-09 | 2024-06-30 | |
| 8-K | 2024-08-07 | — | |
| 8-K | 2024-06-04 | 2024-06-03 | |
| 10-Q | 2024-05-10 | 2024-03-31 | |
| 8-K | 2024-05-08 | — | |
| DEF 14A | 2024-04-12 | 2024-06-03 | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2024-02-28 | — | |
| 8-K | 2023-11-08 | — | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-09-15 | 2023-09-11 | |
| 8-K/A | 2023-08-16 | 2023-06-30 | |
| 10-Q | 2023-08-09 | 2023-06-30 | |
| 8-K | 2023-08-08 | — | |
| 8-K | 2023-06-30 | — | |
| 8-K | 2023-06-06 | 2023-06-05 | |
| 8-K | 2023-05-09 | — | |
| 10-Q | 2023-05-09 | 2023-03-31 |
Showing 1–50 of 100 filings
Key facts
CIK
1297184
CUSIP
03209R103
13F (30d)
169 filings
167 filers
Visit website
Investor relations